We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VBI Vaccines Up on Coronavirus Vaccine Candidates Selection
Read MoreHide Full Article
VBI Vaccines Inc. (VBIV - Free Report) announced that it has selected two pre-clinical candidates as coronavirus vaccine for clinical-stage development. The selection was based on encouraging data from three pre-clinical mouse studies, which evaluated one dose of the candidates. These studies were conducted particularly to enable selection of optimized clinical candidates for the company’s coronavirus program, VBI-2900.
The company selected one trivalent vaccine — VBI-2901 — and a monovalent vaccine — VBI-2902 — to evaluate in a phase I/II study, with the potential to be one-dose vaccines. The study is expected to start toward the end of this year, subject to regulatory approval. VBI-2901 is a pan-coronavirus vaccine candidate, which expresses the SARS-CoV-2 (COVID-19), SARS-CoV (“SARS”), and MERS-CoV (“MERS”) spike proteins. VBI-2902 only expresses the SARS-CoV-2 spike protein.
Shares of VBI Vaccines’ surged more than 32% on Aug 27, following the announcement. The company’s shares have skyrocketed 582.8% in the year so far compared with the industry’s growth of 14.1%.
Please note that the vaccine candidates were developed using VBI Vaccines’ proprietary enveloped virus-like particle (eVLP) platform technology. Data from pre-clinical studies showed that following one dose of vaccine candidates, patients achieved neutralizing antibody binding (nAb) geometric mean titer (“GMT”) four times compared to the GMT of high-titer convalescent sera, individuals who had contracted and recovered from COVID-19 with robust response, naturally. Patients receiving second dose achieved 64 times nAb GMT compared to high-titer convalescent sera.
A single dose of vaccine candidates also induced 10 times antibody binding (Ab) GMT compared to high-titer convalescent sera. Moreover, the trivalent vaccine candidate induced Ab binding titers across COVID-19, SARS, and MERS spike proteins. The candidate was also observed to have reactivity to a seasonal human coronavirus not expressed in the vaccine.
Based on the data from the three pre-clinical studies, the company believes that a single dose of its vaccine candidates may offer protection to individuals against COVID-19, with the trivalent vaccine candidate providing protection against all types of known coronaviruses.
Earlier this month, VBI Vaccines signed an agreement with the Contract Development and Manufacturing Organization, Therapure Biomanufacturing, for development and manufacturing of the vaccine candidates to support clinical studies.
Meanwhile, we note that three coronavirus vaccine candidates from other players have already reached final-stage of development. These are Moderna’s (MRNA - Free Report) mRNA-1273, Pfizer (PFE - Free Report) /BioNTech’s BNT162b program, and Oxford University/AstraZeneca’s (AZN - Free Report) AZD1222. These companies are planning to launch their coronavirus vaccine candidate by the end of this year, subject regulatory approvals. The companies have also signed several supply agreements with different countries for billions of doses of their candidates. However, all these candidates are being developed with a two-dose regimen. The potential of VBI Vaccine’s candidates for a single-dose regimen may prove beneficial following a commercial launch.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q2 2020, while the S&P 500 gained an impressive +44.0%, five of our strategies returned +50.9%, +93.8%, +122.2%, +153.0%, and even +156.8%.
This outperformance has not just been a recent phenomenon. From 2000 – Q2 2020, while the S&P averaged +5.5% per year, our top strategies averaged up to +51.7% per year.
Image: Bigstock
VBI Vaccines Up on Coronavirus Vaccine Candidates Selection
VBI Vaccines Inc. (VBIV - Free Report) announced that it has selected two pre-clinical candidates as coronavirus vaccine for clinical-stage development. The selection was based on encouraging data from three pre-clinical mouse studies, which evaluated one dose of the candidates. These studies were conducted particularly to enable selection of optimized clinical candidates for the company’s coronavirus program, VBI-2900.
The company selected one trivalent vaccine — VBI-2901 — and a monovalent vaccine — VBI-2902 — to evaluate in a phase I/II study, with the potential to be one-dose vaccines. The study is expected to start toward the end of this year, subject to regulatory approval. VBI-2901 is a pan-coronavirus vaccine candidate, which expresses the SARS-CoV-2 (COVID-19), SARS-CoV (“SARS”), and MERS-CoV (“MERS”) spike proteins. VBI-2902 only expresses the SARS-CoV-2 spike protein.
Shares of VBI Vaccines’ surged more than 32% on Aug 27, following the announcement. The company’s shares have skyrocketed 582.8% in the year so far compared with the industry’s growth of 14.1%.
Please note that the vaccine candidates were developed using VBI Vaccines’ proprietary enveloped virus-like particle (eVLP) platform technology. Data from pre-clinical studies showed that following one dose of vaccine candidates, patients achieved neutralizing antibody binding (nAb) geometric mean titer (“GMT”) four times compared to the GMT of high-titer convalescent sera, individuals who had contracted and recovered from COVID-19 with robust response, naturally. Patients receiving second dose achieved 64 times nAb GMT compared to high-titer convalescent sera.
A single dose of vaccine candidates also induced 10 times antibody binding (Ab) GMT compared to high-titer convalescent sera. Moreover, the trivalent vaccine candidate induced Ab binding titers across COVID-19, SARS, and MERS spike proteins. The candidate was also observed to have reactivity to a seasonal human coronavirus not expressed in the vaccine.
Based on the data from the three pre-clinical studies, the company believes that a single dose of its vaccine candidates may offer protection to individuals against COVID-19, with the trivalent vaccine candidate providing protection against all types of known coronaviruses.
Earlier this month, VBI Vaccines signed an agreement with the Contract Development and Manufacturing Organization, Therapure Biomanufacturing, for development and manufacturing of the vaccine candidates to support clinical studies.
Meanwhile, we note that three coronavirus vaccine candidates from other players have already reached final-stage of development. These are Moderna’s (MRNA - Free Report) mRNA-1273, Pfizer (PFE - Free Report) /BioNTech’s BNT162b program, and Oxford University/AstraZeneca’s (AZN - Free Report) AZD1222. These companies are planning to launch their coronavirus vaccine candidate by the end of this year, subject regulatory approvals. The companies have also signed several supply agreements with different countries for billions of doses of their candidates. However, all these candidates are being developed with a two-dose regimen. The potential of VBI Vaccine’s candidates for a single-dose regimen may prove beneficial following a commercial launch.
VBI Vaccines, Inc. Price
VBI Vaccines, Inc. price | VBI Vaccines, Inc. Quote
Zacks Rank
VBI Vaccine currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q2 2020, while the S&P 500 gained an impressive +44.0%, five of our strategies returned +50.9%, +93.8%, +122.2%, +153.0%, and even +156.8%.
This outperformance has not just been a recent phenomenon. From 2000 – Q2 2020, while the S&P averaged +5.5% per year, our top strategies averaged up to +51.7% per year.
See their latest picks free >>